Translational and Clinical Pharmacology

Publications

Ahn, Y; Tiley, JB; Prasad, B; Brouwer, KLR. Lysosomal Membrane Localization of Organic Anion Transporting Polypeptide (OATP) 2B1 in Human Hepatocytes. Drug Metabolism And Disposition. 2026; 100386.

Ailabouni, AS; Halpin, K; Boone, EC; Gaedigk, A; Nadai, T; Irie, K; Mizuno, T; Leeder, JS; Prasad, B. Interindividual variability in metformin pharmacokinetics in pediatric patients. Pediatric Research. 2026.

Aston, B; Matta, M; Leino, A; Shields, A; Ejaz, N; Kaur, T; Parrish, N. Safety and Efficacy of Belatacept in Older Kidney Transplant Recipients. American Journal of Transplantation. 2026; 26(7):s517.

Bartel, C; Mizuno, T; Karns, R; Irie, K; Jackson, K; Lynch, K; Samuels, A; Hyams, JS; Boyle, B; Kurowski, JA; Chun, K; Yang, J; Denson, LA; Minar, P. Evaluation of pharmacokinetic metrics and pharmacodynamic biomarkers associated with endoscopic healing in pediatric Crohn's disease patients treated with anti-tumor necrosis factor biologics. Crohn's & Colitis 360. 2026; 8(3):otag088.

Cleary, Y; Prasad, B; Ogungbenro, K; Gertz, M; Galetin, A. Population Physiologically-Based Pharmacokinetic Modeling to Determine Ontogeny: A Quantitative Clinical Pharmacology Example in Pediatric Rare Disease. CPT: Pharmacometrics and Systems Pharmacology. 2026; 15(2):e70174.

Davydov, DR; Ponraj, K; Davydova, NY; Yue, G; Singh, DK; Neogi, AG; Gaither, KA; Prasad, B. The role of CYP3A-CYP2E1 interactions in activation of CYP3A enzymes by chronic alcohol exposure. Biochemical Journal. 2026; 483(9):1689-1707.

De Hoop-Sommen, MA; Alozai, S; Gijsen, VMGJ; Van Der Zanden, TM; Akinbi, HT; Mizuno, T; Vinks, AA; Greupink, R; De Wildt, SN. Supporting clinical guidelines for opioid conversion to methadone and tapering to prevent withdrawal in critically ill children using physiology based pharmacokinetic modeling and simulation. PLoS ONE. 2026; 21(9):e0356917.

Dewedoff, K; Hoberman, A; Mizuno, T; Vinks, A. P-1241. Pharmacokinetic Comparison of Augmentin ES-600 and a Reduced Concentration Clavulanate Formulation in Young Children; Modeling of amoxicillin/clavulanic acid in vitro effects on bacterial growth and killing and in vivo exposure evaluation. Open Forum Infectious Diseases. 2026; 13(Supplement_1):ofaf695.1433.

Gadara, D; Singh, DK; Subash, S; Yue, G; Ahire, D; Bohl, C; Czerwinski, M; Helmstetter, S; Heyward, S; Jones, RS; Stresser, DM; Taub, ME; Wang, T; Prasad, B. Characterization of Lysosomal Hydrolases and Transporters and Their Age-Dependent Variability: Relevance to Drug Metabolism and Transport of Small Molecule and Biologic Drugs. Clinical Pharmacology and Therapeutics. 2026.

Gaither, KA; Davydova, NY; Ponraj, K; Singh, DK; Prasad, B; Davydov, DR. Impact of alcohol consumption on CYP1A2 activity in human liver microsomes studied with a new naphthalene-based fluorogenic substrate. Drug Metabolism And Disposition. 2026; 54(10):100392.

Gooden, F; Meier, BD; Shaffer, GD; Gibson, K; Toren, P; Punt, NC; Subash, S; Singh, DK; Prasad, B; Ramsey, LB; Taylor, ZL. Pharmacogenetic hSLCO1B1*14-Guided Dosing of Methotrexate in Transgenic Arthritic Mice Normalizes Exposure and Response. Clinical and Translational Science. 2026; 19(1):e70449.

Hambrick, HR; Junior, RM; Curry, C; Collins, M; Johnson, L; Mizuno, T; Krallman, KA; Goldstein, SL; Tang Girdwood, S. Urine NGAL adds to serum creatinine in predicting cefepime clearance in critically ill children at high risk of acute kidney injury. International Journal of Antimicrobial Agents. 2026; 67(5):107741.

Hosawi, A; Irie, K; Dong, M; Ware, J; Ware, R; Mizuno, T. Model-Informed Evaluation of Hydroxyurea Exposure During Lactation. Clinical Pharmacology and Therapeutics. 2026.

Irie, K; Mizuno, T. AI-Enabled Precision Dosing in Pediatrics: Enhancing Model-Informed Decision Making. Clinical Pharmacology and Therapeutics. 2026.

Irie, K; Minar, P; Reifenberg, J; Boyle, BM; Noe, JD; Hyams, JS; Mizuno, T. Machine Learning Modeling for Predicting Infliximab Pharmacokinetics in Pediatric and Young Adult Patients With Crohn Disease: Leveraging Ensemble Modeling With Synthetic and Real-World Data. Therapeutic Drug Monitoring. 2026; 48(1):98-104.

Irie, K; Minar, P; Reifenberg, J; Boyle, BM; Noe, JD; Hyams, JS; Mizuno, T. Model-Informed Deep Q-Networks to Guide Infliximab Dosing in Pediatric Crohn's Disease. Clinical Pharmacology and Therapeutics. 2026; 119(2):555-563.

Jodele, S; Mizuno, K; Sabulski, A; Dandoy, CE; Ramos, KN; Langenberg, L; Luebbering, N; Webster, A; Klink, G; Mclean, S; Davies, SM. Determinants of Eculizumab Response in High-Risk Transplant-Associated Thrombotic Microangiopathy. Transplantation and Cellular Therapy. 2026; 32(2):s104-s105.

Johnson, LSM; Leino, AD; Haver, DB. Public communication and perception of xenotransplantation. Current Opinion in Organ Transplantation. 2026; 31(1):33-40.

Klink, G; Mizuno, K; Teusink, A; Mclean, S; Davies, SM; Jodele, S. A Decade of Precision: PK/PD-Guided Eculizumab Therapy for TA-TMA Management. Transplantation and Cellular Therapy. 2026; 32(2):s615.

Kuo-Esser, L; Vijaywargi, G; Prasad, B; Thakur, A; Aliabouni, AS; Halpin, K; Paine, M. Metabolite Panel for Estimation of Glomerular Filtration Rate (Abstract ID: 226554) Journal of Pharmacology and Experimental Therapeutics. 2026; 393(5):104160.

Minar, PP; Tan, WR; Irie, K; Boyle, BM; Noe, JD; Hyams, JS; Mizuno, T. Mo1634 BRIDGING DRUG EXPOSURE TO BIOCHEMICAL REMISSION: A PK/PD FRAMEWORK TO INDIVIDUALIZE INFLIXIMAB TARGET CONCENTRATIONS IN PEDIATRIC CROHN’S DISEASE. Gastroenterology. 2026; 170(6):s-1221-s-1222.

Minar, PP; Tan, WR; Irie, K; Boyle, BM; Noe, JD; Hyams, JS; Mizuno, T. Mo1634 BRIDGING DRUG EXPOSURE TO BIOCHEMICAL REMISSION: A PK/PD FRAMEWORK TO INDIVIDUALIZE INFLIXIMAB TARGET CONCENTRATIONS IN PEDIATRIC CROHN’S DISEASE. Gastrointestinal Endoscopy. 2026; 103(5):s-1221-s-1222.

Mizuno, T; Neely, MN. Rising Role of Artificial Intelligence in Clinical Pharmacometrics and Model-Informed Precision Dosing in Pediatrics. Journal of Pediatric Pharmacology and Therapeutics. 2026; 31(1):106-111.

Morales Junior, R; Hambrick, HR; Benoit, SW; Klink, G; Mizuno, T; Tang Girdwood, S. Population pharmacokinetics and Monte Carlo simulation of Cefepime in paediatric and Young adult bone marrow transplant patients. British Journal of Clinical Pharmacology. 2026; 92(7):2316-2325.

Morales Junior, R; Mizuno, T; Tan, WR; Irie, K; Tang Girdwood, S. From PICU to NICU: Extrapolating Meropenem Exposure From Pediatric to Neonatal Intensive Care Patients. Journal of Clinical Pharmacology. 2026; 66(1):e70097.

Nasr, A; Mizuno, T; Irie, K; Dillman, JR; Jackson, K; Lynch, K; Horrell, A; Aviles, T; Chun, K; Yang, J; Boyle, B; Hyams, JS; Noe, J; Denson, LA; Minar, P. Pharmacometric Targets During Anti-TNF Induction and Their Association with Deep Remission in Pediatric Crohn's Disease. Clinical Pharmacokinetics. 2026; 65(9):1353-1365.

Pais, GM; Lesnicki, E; Marianski, S; Valdez, K; Gibson, Z; Christopher, J; Lepard, K; Gilchrist, A; Mizuno, T; Scheetz, MH. Elevated hippocampal and cortical cefepime concentrations correlate with seizures in an acute kidney injury rat model. Antimicrobial Agents and Chemotherapy. 2026; 70(4):e0100525.

Parikh, S; Irie, K; Tanaka, R; Nadai, T; Minar, P; Mizuno, T. Physiologically Based Pharmacokinetic Modeling of Vedolizumab in Healthy Adults and Patients with Inflammatory Bowel Disease. Clinical Pharmacokinetics. 2026; 65(9):1377-1388.

Parker, D; Zhang, L; Mcdowell, J; Keedy, S; Keshavan, M; Pearlson, G; Ivleva, E; Gershon, E; Hill, SK; Tamminga, C; Bishop, J; Clementz, B. 644. Neurotransmitter Pathway Polygenic Risk Shows Biotype-Specific Associations With Clinical and Neurocognitive Profiles in Psychosis. Biological Psychiatry. 2026; 99(10):s375-s376.

Prasad, B. Predicting Pharmacokinetic Variability and Drug Interaction Risk Using Omics-Based Biomarkers. Clinical and Translational Science. 2026; 19(5):e70591.

Sabulski, A; Webster, A; Mizuno, K; Luebbering, N; Davies, SM; Jodele, S. Multiomics Reveal Interferon-Induced Cell Senescence As a Novel Mechanism of Eculizumab Resistance in TA-TMA. Transplantation and Cellular Therapy. 2026; 32(2):s594-s595.

Shaffer, GD; Singh, DK; Subash, S; Prasad, B. Proteomic characterization of human kinases across tissue types: Implications for kinase-activated drugs. Drug Metabolism And Disposition. 2026; 54(10):100385.

Shaffer, G; Singh, DK; Subash, S; Prasad, B. Proteomic Characterization of Human Kinases Across Tissue Types: Implications for Kinase Activated Drugs (Abstract ID: 225691) Journal of Pharmacology and Experimental Therapeutics. 2026; 393(5):104195.

Stojanova, J; Murnion, B; Burrows, F; Carlos, L; Mizuno, T; Nadai, T; Irie, K; Helsby, N; Muthiah, K; Day, R. Continuous Subcutaneous Ketamine Infusion May Induce Tacrolimus and Sirolimus Clearance: A Case Report. Pharmacotherapy. 2026; 46(6):e70150.

Subash, S; Ahire, D; Jones, RS; Ma, B; Tian, Y; Wang, T; Khojasteh, SC; Murray, BP; Stresser, DM; Taub, M; Prasad, B. Protein Abundance of Hydrolytic Drug Metabolizing Enzymes in Different Tissues and across Species. Journal of Medicinal Chemistry. 2026; 69(13):15391-15402.

Tamir, S; Paulose, J; Nguyen, A; Gadara, D; Witt, RM; Prasad, B; Hogenesch, JB. A patient-derived mouse model reproduces molecular, neurological, and sleep symptoms of SHINE syndrome. Human Molecular Genetics. 2026; 35(16).

Tanaka, R; Sawaguchi, A; Mizuno, T; Irie, K; Ono, H; Amano, E; Goto, H; Tashiro, S; Tatsuta, R; Yoshikawa, N; Hirano, N; Ihara, K; Itoh, H. Impact of Febrile State on Vancomycin Clearance in Pediatric Patients: Insights From Population Pharmacokinetic Modeling. Pharmaceutical Research. 2026.

Taylor, ZL; Nadai, T; Irie, K; Tan, WR; Parikh, S; Hosawi, A; Van Hoogdalem, MW; Morales Junior, R; Tang Girdwood, S; Leino, AD; Mizuno, K; Vinks, AA; Mizuno, T. Clinical Model-Informed Precision Dosing Consult Service for Accelerating Personalized Medication in Pediatric Patients. Clinical Pharmacology and Therapeutics. 2026.

Tummala, HP; Leino, AD; Rhodes, NJ; Downes, KJ; Scheetz, MH; Pai, MP. Volumetric Microsampling for Patient-Centric Therapeutic Drug Monitoring in Clinical Pharmacology: A Scoping Review. Journal of Clinical Pharmacology. 2026; 66(9):e70290.

Umemura, K; Katsube, Y; Tsuchido, Y; Katada, Y; Hira, D; Kawata, M; Saigo, M; Tsuda, M; Nakagawa, S; Hattori, EY; Arakawa, Y; Date, H; Nagao, M; Terada, T. Efficient Penetration of Terbinafine into Brain Abscesses in a Lung Transplant Recipient with Scedosporiosis: A Short Communication. Therapeutic Drug Monitoring. 2026; 48(1):134-139.

Yang, C; Zhang, L; Liu, J; Li, K; Li, S; Yang, Z; Bishop, JR; Deng, W; Yao, L; Lui, S; Gong, Q. More Severe Brain Network Hierarchy Disorganization in Treatment-Naive Deficit Compared to Non-deficit Schizophrenia and Underlying Neurotransmitter Associations. Schizophrenia Bulletin. 2026; 52(1).

Yee, SW; Prasad, B; Kusuhara, H; Kimoto, E. Integrating renal transporter biomarkers into drug development: Discovery, clinical assessment, and precision medicine. Drug Metabolism and Pharmacokinetics. 2026; 67:101515.

Zhang, L; Lee, AM; Maxim, ZL; Munirathinam, M; Larsen, BS; Georgieff, MK; Keedy, SK; Reilly, JL; Sweeney, JA; Tran, PV; Bishop, JR. Brain-derived extracellular vesicle (BDEV) abundance and BDEV protein associations with clinical phenotypes and treatment response in untreated first-episode psychosis. Brain, Behavior, and Immunity. 2026; 138:106912.

Zhang, L; Tholkes, AJ; Cullen, KR; Gunlicks-Stoessel, ML; Mroz, P; Farley, JF; Johnson, SG; Bishop, JR. Who receives psychiatry-focused pharmacogenomic testing, and is it associated with prescribing patterns and acute care utilisation in depression? Real-world evidence from a large health system. EBioMedicine. 2026; 128:106275.